Activity Overview
This educational activity is an archive of the live presentation held on April 11, 2026.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward attendees of the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer; these include gynecologic oncologists, medical oncologists, advanced practice providers, nurses, pulmonologists, radiologists, and other health care providers involved in the management of patients with ovarian cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe strategies to assess baseline pulmonary function, and select appropriate candidates for ADC therapy in ovarian cancer
- Develop practical monitoring and triage approaches for early detection of ADC-related pulmonary toxicities in patients with ovarian cancer
- Apply evidence-informed, grade-based algorithms for the evaluation, treatment, and follow-up of ADC-related ILD and pneumonitis in patients with ovarian cancer
- Implement multidisciplinary care pathways that engage oncology, pulmonology, radiology, and nursing or advanced practitioners to optimize coordination of care
Kathleen N. Moore, MD, MS, FASCO
Deputy Director and Director Phase 1 Research
Fred and Pamela Buffett Cancer Center at the
University of Nebraska Medical Center
Omaha, NE
Disclosures: Advisor, Consultant, Fee for Service Recipient: Aadi, AbbVie, AstraZeneca, BeOne, BioNTech, Corcept, Daiichi Sankyo, Duality, GSK, Immunogen, Incyte, Janssen, Loxo/Lilly, Merck, Pfizer, PMV, Regeneron, Schrodinger, Verastem, Whitehawk, Zymeworks; Grant/Research Funding (to institution): Allarity, AstraZeneca, Daiichi Sankyo, GSK, Immunocore, Iovance, Regeneron, Schrodinger, Verastem; Royalty or Patent Benefits: UpToDate
Rachel N. Grisham, MD
Associate Attending Physician
Division of Solid Tumor Oncology
Section Head, Ovarian Cancer
Director, GMO Westchester
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Consulting/Advisory Board: AstraZeneca, Corcept, Genmab, GOG Foundation, GSK, Incyclix, Incyte, SpringWorks, Verastem
Rohit Gupta, MD
Associate Professor
Director, Sarcoidosis Center of Excellence at Temple
Advanced Lung Disease and Lung Transplant
Temple Lung Center
Philadelphia, PA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Kinevant, Mallinckrodt, ANI, Incyte, Molecure, BI, GSK, OrphAI; Speakers Bureau: ANI, BI, MNK; Grant/Research Funding: Atyr, FSR, GSK, Kinevant, Molecure, Priovant, XENTRIA
Maida Hafiz, MD
Assistant Professor
Pulmonary, Critical Care and Sleep Medicine
University of Oklahoma
Oklahoma City, OK
Disclosures: Maida Hafiz, MD, has no relevant financial relationships with ineligible companies.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here